Summary:
The AXLerate-OC Study: A Research Study Evaluating the Effect of a New Drug in Subjects with Platinum-Resistant Recurrent Ovarian Cancer.
Why is the AXLerate-OC Study being done?
The AXLerate-OC Study is evaluating the effect of a new drug on survival in subjects with platinum-resistant recurrent ovarian cancer.
Is the AXLerate-OC Study an option for you?
You may be able to participate in the AXLerate-OC Study if all of the following criteria are met:
- You are at least 18 years of age.
- You have been diagnosed with recurrent ovarian, fallopian tube, or peritoneal cancer.
- You have platinum-resistant disease (meaning cancer has returned within 6 months of last platinum-containing treatment or therapy)
- You have received at least 1, but not more than 4, prior treatment regimens since your ovarian cancer diagnosis.
There are other eligibility requirements that the study evaluator will review with you.